Stock analysts at StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
VBI Vaccines Trading Up 1.5 %
VBI Vaccines stock opened at $0.66 on Friday. The stock has a 50-day moving average price of $0.61 and a 200 day moving average price of $0.61. VBI Vaccines has a 52 week low of $0.45 and a 52 week high of $3.47.
VBI Vaccines (NASDAQ:VBIV – Get Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.02). The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.85 million. VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. As a group, equities research analysts expect that VBI Vaccines will post -1.23 earnings per share for the current year.
VBI Vaccines Company Profile
VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
See Also
- Five stocks we like better than VBI Vaccines
- Insider Trading – What You Need to Know
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.